Search Results - "Hong, D. S."

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors by Hong, D. S., Kurzrock, R., Naing, A., Wheler, J. J., Falchook, G. S., Schiffman, J. S., Faulkner, N., Pilat, M. J., O’Brien, J., LoRusso, P.

“…Summary The aim of this study was to determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic profile of E7107 in patients with…”
Get full text

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response by Liu, X, George, G C, Tsimberidou, A M, Naing, A, Wheler, J J, Kopetz, S, Fu, S, Piha-Paul, S A, Eng, C, Falchook, G S, Janku, F, Garrett, C, Karp, D, Kurzrock, R, Zinner, R, Raghav, K, Subbiah, V, Hess, K, Meric-Bernstam, F, Hong, D S, Overman, M J

“…This retrospective study aims to investigate the activity of retreatment with anti-EGFR-based therapies in order to explore the concept of clonal evolution by…”
Get full text

One dimensional electron gas at the LaAlO3/SrTiO3 interface and its transport properties by Hong, D. S., Zhang, H., Zhang, H. R., Zhang, J., Wang, S. F., Chen, Y. S., Shen, B. G., Sun, J. R.

“…Quasi-one-dimensional electron gases (q1DEGs) have been obtained by fabricating LaAlO3 nanowires, using the technique of electrostatic spinning plus post…”
Get full text

In-situ observation of self-regulated switching behavior in WO3-x based resistive switching devices by Hong, D. S., Wang, W. X., Chen, Y. S., Sun, J. R., Shen, B. G.

“…The transmittance of tungsten oxides can be adjusted by oxygen vacancy (Vo) concentration due to its electrochromic property. Here, we report an in-situ…”
Get full text

Body composition and survival in the early clinical trials setting by Veasey Rodrigues, H, Baracos, V.E, Wheler, J.J, Parsons, H.A, Hong, D.S, Naing, A, Fu, S, Falchoock, G, Tsimberidou, A.M, Piha-Paul, S, Chisholm, G, Kurzrock, R

“…Abstract Purpose Delineate the relationships between body composition parameters, 90-day mortality and overall survival, and correlate them with known…”
Get full text

Prognostic value of activated Akt expression in oral squamous cell carcinoma by Lim, J, Kim, J-H, Paeng, J-Y, Kim, M-J, Hong, S-D, Lee, J-I, Hong, S-P

“…Background: Akt is a serine/threonine kinase that plays an important role in tumorigenesis and influences prognosis in several cancers. However, its importance…”
Get full text

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs by Naing, A., Veasey-Rodrigues, H., Hong, D.S., Fu, S., Falchook, G.S., Wheler, J.J., Tsimberidou, A.M., Wen, S., Fessahaye, S.N., Golden, E.C., Aaron, J., Ewer, M.S., Kurzrock, R.

“…Cardiac sequelae from oncologic drugs are important in early cancer drug development. Prolongation of the corrected QT interval (QTc) by noncardiac drugs is…”
Get full text

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy by Wheler, J.J., Falchook, G.S., Tsimberidou, A.M., Hong, D.S., Naing, A., Piha-Paul, S.A., Chen, S.S., Fu, S., Stephen, B., Fok, J.Y., Janku, F., Kurzrock, R.

“…Epidermal growth factor receptor (EGFR) mutations are associated with the response to EGFR inhibitors in patients with non-small-cell lung cancer (NSCLC). We…”
Get full text

Presence of Porphyromonas gingivalis and plasma cell dominance in gingival tissues with periodontitis by Kim, YC, Ko, Y, Hong, S-D, Kim, KY, Lee, YH, Chae, C, Choi, Y

“…Oral Diseases (2010) 16, 375–381 Objective:  Porphyromonas gingivalis can invade and survive within its host epithelial cells. The aim of this study was to…”
Get full text

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes by Henary, H., Hong, D.S., Falchook, G.S., Tsimberidou, A., George, G.C., Wen, S., Wheler, J., Fu, S., Naing, A., Piha-Paul, S., Janku, F., Kim, K.B., Hwu, P., Kurzrock, R.

“…The purpose of the study was to assess the outcome of patients with advanced melanoma treated with matched molecularly targeted therapy. We reviewed 160…”
Get full text

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience by Wheler, J.J., Tsimberidou, A.M., Hong, D.S., Naing, A., Falchook, G.S., Fu, S., Moulder, S., Stephen, B., Wen, S., Kurzrock, R.

“…This study assessed toxicity in advanced cancer patients treated in a phase I clinic that focuses on targeted agents. An analysis of database records of 1181…”
Get full text

Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies by Falchook, G. S., Duvic, M., Hong, D. S., Wheler, J., Naing, A., Lim, J., Kurzrock, R.

“…Background Preclinical data suggest synergistic activity of bortezomib, gemcitabine, and liposomal doxorubicin. Because tolerance to therapy may be attenuated…”
Get full text

Patterns of hearing loss after microvascular decompression for hemifacial spasm by Park, K, Hong, S H, Hong, S D, Cho, Y-S, Chung, W-H, Ryu, N Gyu

“…Background:The purpose of this study was to analyse audiological data after microvascular decompression (MVD) for hemifacial spasm (HFS), and to compare the…”
Get full text

A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer by Park, K. H., Sohn, J. H., Lee, S., Park, J. H., Kang, S. Y., Kim, H. Y., Park, I. H., Park, Y. H., Im, Y. H., Lee, H. J., Hong, D. S., Park, S., Shin, S. H., Kwon, H. C., Seo, J. H.

“…Summary Backgrounds A pegylated form of recombinant granulocyte-colony stimulating factor (G-CSF) was developed for prophylactic use in breast cancer. The aim…”
Get full text

Cognition and behavior in Turner syndrome: a brief review by Hong, D S, Reiss, A L

“…There is increasing evidence that Turner syndrome is associated with a distinct pattern of cognitive and neurophysiological characteristics. Typically this has…”
Get more information

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge by Parseghian, C.M., Loree, J.M., Morris, V.K., Liu, X., Clifton, K.K., Napolitano, S., Henry, J.T., Pereira, A.A., Vilar, E., Johnson, B., Kee, B., Raghav, K., Dasari, A., Wu, J., Garg, N., Raymond, V.M., Banks, K.C., Talasaz, A.A., Lanman, R.B., Strickler, J.H., Hong, D.S., Corcoran, R.B., Overman, M.J., Kopetz, S.

“…Colorectal cancer (CRC) has been shown to acquire RAS and EGFR ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor (EGFR)…”
Get full text

Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors by Galsky, M.D., Camacho, L.H., Chiorean, E.G., Mulkerin, D., Hong, D.S., Oh, W.K., Bajorin, D.F.

“…Satraplatin is an oral platinum analog with demonstrated activity in a range of malignancies. The current study was designed to evaluate the effect of varying…”
Get full text

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study by Hong, D.S., Bauer, T.M., Lee, J.J., Dowlati, A., Brose, M.S., Farago, A.F., Taylor, M., Shaw, A.T., Montez, S., Meric-Bernstam, F., Smith, S., Tuch, B.B., Ebata, K., Cruickshank, S., Cox, M.C., Burris, H.A., Doebele, R.C.

“…NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a potent and highly selective ATP-competitive…”
Get full text

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial by Schuler, M., Berardi, R., Lim, W.-T., de Jonge, M., Bauer, T.M., Azaro, A., Gottfried, M., Han, J.-Y., Lee, D.H., Wollner, M., Hong, D.S., Vogel, A., Delmonte, A., Akimov, M., Ghebremariam, S., Cui, X., Nwana, N., Giovannini, M., Kim, T.M.

“…Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs in 3%–4% of non-small-cell lung cancer (NSCLC) and is associated with unfavorable…”
Get full text

Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib study by Hobbs, B.P., Kane, M.J., Hong, D.S., Landin, R.

“…Within the evidentiary hierarchy of experimental inquiry, randomized trials are the gold standard. Oncology patients enter clinical studies with diverse…”
Get full text